A DNA test like MyBody-X is useful when it targets well-validated, clinically relevant genetic variants. This includes pharmacogenetic markers such as rs9923231 in VKORC1, which strongly influences warfarin dosing (GWAS, p=3e-181). The ADH1B SNP rs1229984 also has moderate evidence for altered alcohol metabolism. For most other areas—such as supplement stacks, nutrition, or fitness—the evidence is weak. Studies on multi-ingredient stacks are extremely limited, and no validated genetic tests guide personalized supplement selection. Furthermore, consumer tests are not diagnostic and do not replace medical advice. The main value lies in raising awareness of known genetic risks, not in providing precise action plans. Without clinical interpretation, the test can easily lead to misguided decisions.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-395b267cd68ed6cb19fb305d